Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

被引:34
|
作者
Ramus, Susan J. [2 ]
Antoniou, Antonis C. [1 ]
Kuchenbaecker, Karoline B.
Soucy, Penny [3 ,4 ]
Beesley, Jonathan [5 ]
Chen, Xiaoqing [5 ]
McGuffog, Lesley
Sinilnikova, Olga M. [6 ,7 ]
Healey, Sue [5 ]
Barrowdale, Daniel
Lee, Andrew
Thomassen, Mads [8 ]
机构
[1] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge CB1 8RN, England
[2] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
[3] Univ Laval, Quebec City, PQ, Canada
[4] Ctr Hosp Univ Quebec, Canc Genom Lab, Quebec City, PQ, Canada
[5] Queensland Inst Med Res, Genet & Populat Hlth Div, Herston, Qld 4006, Australia
[6] Ctr Hosp Univ Lyon, Ctr Leon Berard, Unite Mixte Genet Constitut Canc Frequents, Lyon, France
[7] Univ Lyon 1, INSERM, CNRS, Ctr Rech Cancerol Lyon,U1052,UMR5286, F-69365 Lyon, France
[8] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense, Denmark
基金
加拿大健康研究院; 英国医学研究理事会; 美国国家卫生研究院; 俄罗斯基础研究基金会; 澳大利亚国家健康与医学研究理事会; 芬兰科学院;
关键词
ovarian cancer; BRCA1; BRCA2; association; SNP; GENOME-WIDE ASSOCIATION; BREAST-CANCER; POPULATION; LOCUS; 8Q24; POSITION; 9P22.2; 1P11.2;
D O I
10.1002/humu.22025
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in BRCA2 carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.670.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.211.83) P-trend = 1.8 x 10-4, rs717852 HR = 1.25 (95% CI: 1.101.42) P-trend = 6.6 x 10-4, rs9303542 HR = 1.16 (95% CI: 1.021.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in BRCA1 carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.810.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.101.42) P-trend = 6.1 x 10-4. The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with BRCA1 and BRCA2 mutations regarding their risk of ovarian cancer. Hum Mutat 33:690702, 2012. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:690 / 702
页数:13
相关论文
共 50 条
  • [1] Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
    Xia, Yue Yin
    Lubinski, Jan
    Rosen, Barry
    Moller, Pal
    Eisen, Andrea
    Ainsworth, Peter
    Senter, Leigha
    Neuhausen, Susan
    Singer, Christian
    Brooks, Jennifer
    Sun, Ping
    Narod, Steven
    Kotsopoulos, Joanne
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 : S50 - S51
  • [2] Weight gain and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Kim, Shana
    Lubinski, Jan
    Huzarski, Tomasz
    Moller, Pal
    Armel, Susan
    Karlan, Beth
    Senter, Leigha
    Eisen, Andrea
    Foulkes, William
    Singer, Christian
    Tung, Nadine
    Bordeleau, Louise
    Neuhausen, Susan
    Olopade, Olufunmilayo
    Eng, Charis
    Weitzel, Jeffrey
    Fruscio, Robert
    Narod, Steven
    Kotsopoulos, Joanne
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 : S357 - S358
  • [3] Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers
    Kim, Shana J.
    Lubinski, Jan
    Huzarski, Tomasz
    Moller, Pal
    Armel, Susan
    Karlan, Beth Y.
    Senter, Leigha
    Eisen, Andrea
    Foulkes, William D.
    Singer, Christian F.
    Tung, Nadine
    Bordeleau, Louise
    Neuhausen, Susan L.
    Olopade, Olufunmilayo, I
    Eng, Charis
    Weitzel, Jeffrey N.
    Fruscio, Robert
    Narod, Steven A.
    Kotsopoulos, Joanne
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2021, 30 (11) : 2038 - 2043
  • [4] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Milne, Roger L.
    Osorio, Ana
    Ramon y Cajal, Teresa
    Baiget, Montserrat
    Lasa, Adriana
    Diaz-Rubio, Eduardo
    de la Hoya, Miguel
    Caldes, Trinidad
    Teule, Alex
    Lazaro, Conxi
    Blanco, Ignacio
    Balmana, Judith
    Sanchez-Olle, Gessami
    Vega, Ana
    Blanco, Ana
    Chirivella, Isabel
    Esteban Cardenosa, Eva
    Duran, Mercedes
    Velasco, Eladio
    Martinez de Duenas, Eduardo
    Tejada, Maria-Isabel
    Miramar, Maria-Dolores
    Calvo, Maria-Teresa
    Guillen-Ponce, Carmen
    Salazar, Raquel
    San Roman, Carlos
    Urioste, Miguel
    Benitez, Javier
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 221 - 232
  • [5] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Roger L. Milne
    Ana Osorio
    Teresa Ramón y Cajal
    Montserrat Baiget
    Adriana Lasa
    Eduardo Diaz-Rubio
    Miguel de la Hoya
    Trinidad Caldés
    Alex Teulé
    Conxi Lázaro
    Ignacio Blanco
    Judith Balmaña
    Gessamí Sánchez-Ollé
    Ana Vega
    Ana Blanco
    Isabel Chirivella
    Eva Esteban Cardeñosa
    Mercedes Durán
    Eladio Velasco
    Eduardo Martínez de Dueñas
    María-Isabel Tejada
    María-Dolores Miramar
    María-Teresa Calvo
    Carmen Guillén-Ponce
    Raquel Salazar
    Carlos San Román
    Miguel Urioste
    Javier Benítez
    Breast Cancer Research and Treatment, 2010, 119 : 221 - 232
  • [6] Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Kotsopoulos, Joanne
    Lubinski, Jan
    Gronwald, Jacek
    Cybulski, Cezary
    Demsky, Rochelle
    Neuhausen, Susan L.
    Kim-Sing, Charmaine
    Tung, Nadine
    Friedman, Susan
    Senter, Leigha
    Weitzel, Jeffrey
    Karlan, Beth
    Moller, Pal
    Sun, Ping
    Narod, Steven A.
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (05) : 1136 - 1146
  • [7] ASPIRIN USE AND RISK OF OVARIAN CANCER AMONG BRCA1 AND BRCA2 MUTATION CARRIERS
    Kotsopoulos, J.
    Lubinski, J.
    Demsky, R.
    Kim-Sing, C.
    Tung, N.
    Karlan, B.
    Sun, P.
    Narod, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 308 - 308
  • [8] ASPIRIN USE AND RISK OF OVARIAN CANCER AMONG BRCA1 AND BRCA2 MUTATION CARRIERS
    Kotsopoulos, J.
    Lubinski, J.
    Demsky, R.
    Kim-Sing, C.
    Tung, N.
    Karlan, B.
    Sun, P.
    Narod, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1553 - 1553
  • [9] Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Kotsopoulos, J
    Lubinski, J
    Neuhausen, SL
    Lynch, HT
    Rosen, B
    Ainsworth, P
    Moller, P
    Ghadirian, P
    Isaacs, C
    Karlan, B
    Sun, P
    Narod, SA
    GYNECOLOGIC ONCOLOGY, 2006, 100 (01) : 83 - 88
  • [10] IMPACT OF PREGNANCY ON THE RISK OF BREAST AND OVARIAN CANCER IN BRCA1 AND BRCA2 MUTATION CARRIERS
    Russo, M.
    Corvetto, E.
    Fais, M.
    Candotti, G.
    Locati, V.
    Proto, A.
    Angioni, S.
    Carcassi, C.
    Mais, V.
    Peiretti, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A391 - A391